RayKnowChina Research Map
Shortlist0

Hangzhou

First Affiliated Hospital of Zhejiang Chinese Medical University

浙江中医药大学附属第一医院(浙江省中医院)

Listed for 15 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at First Affiliated Hospital of Zhejiang Chinese Medical University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Stomach cancer胃癌29 papers led
  2. Osteosarcoma骨肉瘤2 papers led
  3. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  4. Multiple myeloma多发性骨髓瘤2 papers led
  5. Aplastic anaemia再生障碍性贫血24 papers led1 open trial led
  6. Haemophilia A血友病 A23 papers led
  7. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  8. Myasthenia gravis重症肌无力4 papers led
  9. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎1 paper led
  10. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  11. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  12. Fabry disease法布雷病1 paper led
  13. Behçet disease白塞病2 papers led
  14. IgA nephropathyIgA 肾病2 papers led
  15. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Neuroblastoma, Ewing sarcoma, B-cell acute lymphoblastic leukaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Stomach cancer

胃癌

Led 29 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
29
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 6620232024: 7720242025: 13132025

9 hospitals in Hangzhou for stomach cancer218 hospitals in China for stomach cancer

No open trial on stomach cancer lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesEarly detection & endoscopyImaging & AIImmunotherapy & targeted drugs
Departments in papersGastroenterology / hepatologyMedical oncologyRadiology / nuclear medicinePathology / laboratory medicine
Papers it led29
  1. TRIM24 promotes proliferation and metastasis of gastric cancer via mediating NRBP1 ubiquitination.2025Cell death & diseaseFree full text
  2. Mechanisms of Traditional Chinese Medicine in Advanced Gastric Cancer: Insights from Meta-Analysis and Network Pharmacology.2025Complementary medicine research
  3. Establishment and Validation of Lactate Metabolism-Related Genes as a Prognostic Model for Gastric Cancer.2025Current molecular medicine
  4. Huashi Jiedu Decoction Enhances 5-Fluorouracil Efficacy in Gastric Cancer via miRNA-21-3p/p53 Pathway.2025Drug design, development and therapyFree full text
  5. Unveiling the Novel Anti - Tumor Potential of Digitonin, a Steroidal Saponin, in Gastric Cancer: A Network Pharmacology and Experimental Validation Study.2025Drug design, development and therapyFree full text
  6. A review of potential mechanisms and treatments of gastric intestinal metaplasia.2025European journal of gastroenterology & hepatology
  7. The impact of aberrant lipid metabolism on the immune microenvironment of gastric cancer: a mini review.2025Frontiers in immunologyFree full text
  8. Reprogramming tumor-associated macrophages in gastric cancer: a pathway to enhanced immunotherapy.2025Frontiers in immunologyFree full text
  9. Advances in the Treatment of Gastric Artificial Ulcers Following Endoscopic Submucosal Dissection (ESD).2025Journal of digestive diseases
  10. The Role of Endoscopic Grading of Gastric Intestinal Metaplasia (EGGIM) in Assessing the Extent and Degree of Gastric Intestinal Metaplasia.2025Journal of digestive diseasesFree full text
  11. Integrative multiomics analysis reveals the subtypes and key mechanisms of platinum resistance in gastric cancer: identification of KLF9 as a promising therapeutic target.2025Journal of translational medicineFree full text
  12. Machine learning-driven risk stratification for distant metastasis in gastric cancer: A comparative study of clinical features and composite indices integrated models.2025PloS oneFree full text
  13. Identification of an extracellular matrix signature for predicting prognosis and sensitivity to therapy of patients with gastric cancer.2025Scientific reportsFree full text
  14. Convolutional neural network applied to preoperative venous-phase CT images predicts risk category in patients with gastric gastrointestinal stromal tumors.2024BMC cancerFree full text
  15. Qingrexiaoji Recipe Regulates the Differentiation of M2 TAM via miR-29 in GC.2024Combinatorial chemistry & high throughput screening
  16. Curcumol Enhances the Sensitivity of Gastric Cancer to Cisplatin Resistance by Inducing Ferroptosis Through the P62/KEAP1/NRF2 Pathway.2024Integrative cancer therapiesFree full text
  17. Letter to the Editor for the article 'A nomogram incorporating treatment data for predicting overall survival in gastroenteropancreatic neuroendocrine tumors: a population-based cohort study'.2024International journal of surgery (London, England)Free full text
  18. The efficacy and safety of per-nasal "GTS partner" assisted traction technique for gastric endoscopic submucosal dissection: a prospective single-center randomized clinical trial.2024Surgical endoscopyRCTFree full text
  19. Ability of detection in different resolution endoscopy for upper gastrointestinal mucosal lesions.2024Surgical endoscopyFree full text
  20. Impact of endoscopic surveillance on the early diagnosis and endoscopic resection likelihood of gastric cancer.2024Surgical endoscopy
  21. An unexpected gastric submucosal mass-like lesion.2023EndoscopyFree full text
  22. Establishment of a modified Kyoto classification scoring model and its significance in the diagnosis of Helicobacter pylori current infection.2023Gastrointestinal endoscopy
  23. Comprehensive bioinformatics and experimental analysis of SH3PXD2B reveals its carcinogenic effect in gastric carcinoma.2023Life sciences
  24. The significance of endoscopic Kyoto classification of gastritis in the gastric cancer risk assessment: A systematic review and meta‑analysis.2023MedicineFree full text
  25. Clinical prognostic value of OSGIN2 in gastric cancer and its proliferative effect in vitro.2023Scientific reportsFree full text
  26. Magnifying endoscopy is superior at detecting easy-missed neoplastic lesions on the upper gastrointestinal tract.2023Surgical endoscopy
  27. Identification of AKIRIN2 as a potential biomarker and correlation with immunotherapy in gastric adenocarcinoma by integrated bioinformatics analysis.2022Scientific reportsFree full text
  28. Comparison of S-1-based vs. capecitabine-based adjuvant chemotherapy for patients with gastric cancer: a systematic review and meta-analysis.2021European journal of clinical pharmacology
  29. Performance evaluation of four prediction models for risk stratification in gastric cancer screening among a high-risk population in China.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Chinese-language papers (not in the count)3
  1. [Clinical, endoscopic, and pathological analyses of 14 cases of gastric adenocarcinoma of the fundic gland type].2024Zhonghua nei ke za zhi
  2. [The value of OLGA staging system in risk assessment of gastric precancerous states and precancerous lesions].2022Zhonghua yi xue za zhi
  3. [A comparative study of new gastric cancer screening scoring system and new ABC method for screening gastric cancer and precancerous lesions].2021Zhonghua nei ke za zhi
All its trials on ClinicalTrials.gov, any status3
  1. A Feasibility Study for Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in ELM Gastric CancerStatus unknownNCT03258034Lead sponsorPhase 2Start 2017-08
  2. Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric CancerStatus unknownNCT02529878Lead sponsorPhase 2Start 2015-08
  3. The Research of Constructing a Risk Assessment Model for Gastric Cancer Based on Machine LearningStatus unknownNCT04957407Study siteStart 2019-01

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 2 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

22 hospitals in Hangzhou for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

16 hospitals in Hangzhou for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 2 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.1%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

9 hospitals in Hangzhou for multiple myeloma178 hospitals in China for multiple myeloma

No open trial on multiple myeloma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis, MRD & riskBispecific & antibody drugs

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 24 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 5.8%.

Papers led
24
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 4420222023: 7720232024: 4420242025: 772025

5 hospitals in Hangzhou for aplastic anaemia63 hospitals in China for aplastic anaemia

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Treatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical Study
    Phase
    N/A
    Started
    2025-05
    Registry
    NCT06964971

    Age 18 years to 80 years (registered criteria)

    Led by First Affiliated Hospital of Zhejiang Chinese Medical UniversityHangzhou

  2. Recruiting
    A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic Anemia
    Phase
    N/A
    Started
    2025-10
    Registry
    NCT07499284

    Age 14 years to Not stated (registered criteria)

    Led by First Affiliated Hospital of Soochow University; 2 listed hospitals as study sitesHangzhou, Suzhou, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesStem cell transplantImmunosuppressive treatmentClonal evolution & PNH
Departments in papersRadiology / nuclear medicinePathology / laboratory medicine
Papers it led24
  1. Effect of home-based exercise program on patients with aplastic anemia treated with allogeneic hematopoietic stem cell transplantation: a non-randomized trial.2026Journal of cancer survivorship : research and practice
  2. Hematopoietic stem cell transplantation and immunosuppressive therapy: implications of clonal haematopoiesis.2025Annals of hematologyFree full text
  3. Clinical characteristic of isolated thrombocytopenia in patients with bone marrow failure-related germline variants: a retrospective study from a single centre.2025Annals of medicineFree full text
  4. Initial periodontal therapy for seven patients with aplastic anemia and drug-induced gingival overgrowth: a case series report.2025BMC oral healthFree full text
  5. Efficacy and safety of hematopoietic stem cell transplantation vs. immunosuppressive therapy in patients with hepatitis-associated aplastic anemia: a systematic review and meta-analysis.2025Hematology (Amsterdam, Netherlands)
  6. Shisiwei Jianzhong decoction inhibits the adipogenic differentiation of bone marrow mesenchymal stem cells by downregulating nuclear factor of activated T cells, cytoplasmic 4 in non-severe aplastic anemia.2025Journal of traditional Chinese medicine = Chung i tsa chih ying wen panFree full text
  7. Post-traumatic growth experience with kinship hematopoietic stem cells transplantation in patients with aplastic anemia: A qualitative study.2025PloS oneFree full text
  8. The Optimal Adjuvant Reinfusion Strategy for Aplastic Anemia: Umbilical Cord Blood or Mesenchymal Stem Cells? A Single-Center Retrospective Study.2025Transplantation and cellular therapy
  9. A potential predictive model based on machine learning and CPD parameters in elderly patients with aplastic anemia and myelodysplastic neoplasms.2024BMC medical informatics and decision makingFree full text
  10. Integrating network pharmacology and experimental validation to explore the mitophagy-associated pharmacological mechanism of modified Shisiwei Jianzhong decoction against aplastic anemia.2024Biomedical chromatography : BMC
  11. Germline variants in acquired aplastic anemia: current knowledge and future perspectives.2024HaematologicaFree full text
  12. Effectiveness of exercise rehabilitation on aplastic anemia patients receiving hematopoietic stem cell transplantation: study protocol for a randomized controlled trial.2024TrialsFree full text
  13. Comparison of haploidentical-allogeneic hematopoietic stem cell transplantation and intensive immunosuppressive therapy for patients with severe aplastic anemia with an absolute neutrophil count of zero: a retrospective study.2023Annals of hematology
  14. Whole-exome sequencing identifies FANC heterozygous germline mutation as an adverse factor for immunosuppressive therapy in Chinese aplastic anemia patients aged 40 or younger: a single-center retrospective study.2023Annals of hematologyFree full text
  15. Comparison of anti-thymocyte globulin-based immunosuppressive therapy and allogeneic hematopoietic stem cell transplantation in patients with transfusion-dependent non-severe aplastic anaemia: a retrospective study from a single centre.2023Annals of medicineFree full text
  16. Quantitative analysis of pelvic bone marrow fat using an MRI-based machine learning method for distinguishing aplastic anaemia from myelodysplastic syndromes.2023Clinical radiology
  17. Research progress on the hematopoietic microenvironment in aplastic anemia.2023European journal of haematology
  18. Panaxadiol saponin ameliorates ferroptosis in iron-overload aplastic anemia mice and Meg-01 cells by activating Nrf2/HO-1 and PI3K/AKT/mTOR signaling pathway.2023International immunopharmacology
  19. Experience of life quality from patients with aplastic anemia: a descriptive qualitative study.2023Orphanet journal of rare diseasesFree full text
  20. Treatment of Chronic Aplastic Anemia with Chinese Patent Medicine Pai-Neng-Da Capsule () for Replacing Androgen Partially: A Clinical Multi-Center Study.2022Chinese journal of integrative medicineRCT
  21. Acute rhabdomyolysis in hepatitis-associated aplastic anemia patient undergoing allogeneic hematopoietic stem-cell transplantation: case report and literature review.2022European journal of medical researchFree full text
  22. Apolipoprotein-A is a potential prognostic biomarker for severe aplastic anemia patients treated with ATG-based immunosuppressive therapy: a single-center retrospective study.2022Lipids in health and diseaseFree full text
  23. Icariin protects bone marrow mesenchymal stem cells in aplastic anemia by targeting MAPK pathway.2022Molecular biology reports
  24. Quantifying Bone Marrow Fat Fraction and Iron by MRI for Distinguishing Aplastic Anemia from Myelodysplastic Syndromes.2021Journal of magnetic resonance imaging : JMRIFree full text
Chinese-language papers (not in the count)1
  1. [Causal relationship between autoimmune diseases and aplastic anemia: A Mendelian randomization study].2025Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
All its trials on ClinicalTrials.gov, any status2
  1. Treatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical StudyNot yet recruitingNCT06964971Lead sponsorN/AStart 2025-05
  2. A Multicenter, Randomized, Open-Label Study of Haplo-Cord HSCT for the Treatment of Aplastic AnemiaRecruitingNCT07499284Study siteN/AStart 2025-10

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 23 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 8.5%.

Papers led
23
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 3320232024: 7720242025: 992025

9 hospitals in Hangzhou for haemophilia A160 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led23
  1. The impact of individualized prophylactic treatment based on pharmacokinetic parameters on the prognosis of patients with severe hemophilia A.2026Expert review of hematology
  2. Decision experiences in joint replacement surgery for patients with haemophilic arthritis: A qualitative study.2025BMC medical informatics and decision making
  3. A retrospective study of rehabilitation for patients with hemophilia knee osteoarthritis after total knee arthroplasty: a 10 year cohort study.2025BMC musculoskeletal disorders
  4. Vascular embolization combined with amputation for recurrent hemophilic pseudotumor.2025BMC musculoskeletal disorders
  5. Prosthesis survival situation and complications following total hip arthroplasty in hemophilic patients: a systematic review.2025BMC musculoskeletal disorders
  6. Total knee arthroplasty for ankylosed knees in the extended position with hemophilia: a medium- and long-term single-center experience.2025BMC surgery
  7. The Role of Posterior Tibial Slope in Range of Motion After Total Knee Arthroplasty for Haemophilia Patients: A Retrospective Study.2025Haemophilia : the official journal of the World Federation of Hemophilia
  8. Comparison of Single Knee Arthroplasty and Bilateral Knee Arthroplasty in Haemophiliacs During a Single Operation: A Systematic Review and Meta-Analysis.2025Haemophilia : the official journal of the World Federation of Hemophilia
  9. How does the Dorr classification of proximal femur affect the total hip arthroplasty of hemophilic patients: a retrospective study.2025Scientific reports
  10. Efficacy of corticosteroids addition to multimodal cocktail periarticular injection in total knee arthroplasty with hemophilic arthropathy.2025Scientific reports
  11. Crohn's disease in hemophilic arthropathy patient: a case report.2024BMC musculoskeletal disorders
  12. A qualitative study on the perioperative experiences and demands of haemophilic arthropathy patients undergoing total joint replacement.2024Haemophilia : the official journal of the World Federation of Hemophilia
  13. Intra-articular injection of tranexamic acid in patients with haemophilia arthritis: retrospective controlled study in total knee arthroplasty.2024International orthopaedics
  14. Risk of low bone mineral density in patients with haemophilia: a systematic review and meta-analysis.2024Journal of orthopaedic surgery and research
  15. Clinical Efficacy of Intra-articular Tranexamic Acid Injection in the Management of Hemophilia with Total Hip Arthroplasty: A 24-month Retrospective Cohort Study.2024Orthopaedic surgery
  16. Bleeder's Femur: The Proximal Femoral Morphology in Hemophilic Patients Who Underwent Total Hip Arthroplasty.2024Orthopaedic surgery
  17. Aberrant methylation and expression of TNXB promote chondrocyte apoptosis and extracullar matrix degradation in hemophilic arthropathy via AKT signaling.2024eLife
  18. Total hip and knee arthroplasty in HIV- and HCV-positive hemophilia patients: short term follow-up of 14 patients.2023BMC musculoskeletal disorders
  19. Physical therapy for end-stage hemophilic arthropathy: a case report.2023BMC musculoskeletal disorders
  20. Osteoporosis and associated risk factors in patients with severe hemophilia A: a case-control study from China.2023BMC musculoskeletal disorders
  21. Hidden blood loss of total knee arthroplasty in hemophilia arthritis: an analysis of influencing factors.2022BMC musculoskeletal disorders
  22. Inflammation, angiogenesis and sensory nerve sprouting in the synovium of bony ankylosed and not bony ankylosed knees with end-stage haemophilic arthropathy.2021Haemophilia : the official journal of the World Federation of Hemophilia
  23. Pathological mechanism of joint destruction in haemophilic arthropathy.2021Molecular biology reports
Earlier papers (2016–2020)1
  1. Femoral head fracture in a haemophilic arthropathy patient: a case report from China.2017Haemophilia : the official journal of the World Federation of Hemophilia
All its trials on ClinicalTrials.gov, any status1
  1. Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia ACompletedNCT02634723Study siteStart 2015-12

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

5 hospitals in Hangzhou for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 4 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 2220242025: 002025

6 hospitals in Hangzhou for myasthenia gravis93 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesAntibodies & diagnosis
Departments in papersPathology / laboratory medicineNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 1 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

6 hospitals in Hangzhou for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

9 hospitals in Hangzhou for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

11 hospitals in Hangzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 1 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 1.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

7 hospitals in Hangzhou for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 2 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

7 hospitals in Hangzhou for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrologyOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

15 hospitals in Hangzhou for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

11 hospitals in Hangzhou for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

浙江中医药大学附属第一医院(浙江省中医院)

First Affiliated Hospital of Zhejiang Chinese Medical University

杭州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Zhejiang Provincial Hospital of Traditional Chinese Medicine; Zhejiang Provincial Hospital of Chinese Medicine; Zhejiang Provincial Hospital of TCM; 浙江省中医院

Suggest a correctionDownload the data